Independence Blue Cross, Excellus Hit Brakes on Some Accelerated Approval Drugs
-
Jan 09, 2025
In a move that has raised the hackles of some stakeholders, Independence Blue Cross (IBX) on Jan. 1 implemented a policy stating that the Philadelphia-based health insurer will not cover nine drugs until 18 months after they received accelerated approval. And IBX does not appear to be the only Blue Cross Blue Shield carrier with such a policy.
IBX, for its part, argues that it is trying to ensure patients are getting only safe and effective treatments — which do not include drugs with minimal data verifying their value.
Read more© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.